Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

NCT05641298 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Corporate finances

Conditions

Cystic Fibrosis
Cystic Fibrosis Pulmonary Exacerbation

Interventions

DRUG: Sodium Fusidate
DRUG: Placebo

Sponsor

Aceragen